MAPT and Cognitive impairment: While administration of recombinant oligomeric tau significantly impaired the performance of control animals, the performance of the tau‐infused LCMT‐1‐overexpressing animals was comparable to that of vehicle‐treated animals, suggesting that LCMT‐1 overexpression protects against cognitive impairments caused by extracellularly applied tau (Figure 1A).